45 clinical trials
grid
list
download
- Title Organ Phase Statut Major inclusion criteria Contact
- 1367.1 An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies, with repeated administration in patients with clinical benefit Multiple phase 1 Closed any line, RECIST 1.1
- ADRIATIC A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III Limited Disease Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (D933QC00001 - ADRIATIC) Lung phase 3 Closed 4 lines chemotherapy and radiation
- AMC303-01 A safety, tolerability and pharmacokinetic dose escalation expansion, Phase I/Ib study of AMC303 as monotherapy in patients with advanced or metastatic, malignant solid tumour of epithelial origin Multiple phase 1/1b Closed any line, RECIST 1.1
- AMG510 A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation Multiple phase 1/2 Closed Locally-advanced or metastatic malignancy with : KRAS p.G12Cmutation
- ANAM-17-21 A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of Anamorelin HCL for the treatment of malignancy associated weight loss and anorexia in adult patients with advanced nonsmall cell lung cancer (NSCLC) NSCLC phase 3 Closed Ongoing problemn with apetite/eating. Maximum 3 lines of systemic prior
- Apple APPLE trial: Feasibility and activity of AZD9291 (osimertinib) treatment on Positive PLasma T790M in EGFR mutant NSCLC patients Lung phase 3 Closed EGFR activating mutation associated with EGFR-TKI sensitivity
- ARTEMIDE-01 A Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD2936 Anti TIGIT/Anti-PD-1 Bispecific Antibody in Participants with Advanced or Metastatic Non small Cell Lung Cancer (ARTEMIDE-01)(D7020C00001) Lung phase 1/2 Open
- B079201215796 Role of bronchoscopy assisted by electromagnetic navigation (EMN) in the diagnosis of small pulmonary nodules of indeterminate nature. A prospective study by the European Lung Cancer Working Party Lung phase 2 Open Nodule 5-20 mm of undetermined nature in at least one lung.
-
B079201523324
Does inflammation have a significant implication in Lung Cancer evolution?
Lung
Closed
Lung cancer
No prior treatment - BLU-667-2303 A Randomized, Open-Label, Phase 3 Study of Pralsetinib versus Standard of Care for First Line Treatment of RET fusion-positive, Metastatic Non-Small Cell Lung Cancer Lung phase 3 Closed RET-fusion
- CANFOUR An open label, dose escalation followed by dose expansion, safety and tolerability trial of CAN04, a fully humanized monoclonal antibody against IL1RAP, in subjects with solid malignant tumors Multiple phase 1/2 Open Metastatic
- CANOPY-N A randomized, open-label, phase II study of canakinumab or pembrolizumab as monotherapy or in combination as neoadjuvant therapy in subjects with resectable non-small cell lung cancer (CANOPY-N) Lung phase 2 Closed
- CIS-DPI-01 A Phase I/IIa First-in-Human Single-arm Open-label Multicentre Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Ascending Doses of a Cisplatin-based Formulation Administered as Dry Powder for Inhalation in Combination with First Line Standard of Care in Patients with Stage IV Non-Small Cell Lung Cancer (CIS-DPI-01) Lung phase 1/2a Open
- CLDK378A2303 A Phase III, multicenter, randomized, open-label study of oral LDK378 versus standard chemotherapy in adult patients with ALK-rearranged (ALK-positive) advanced non-small cell lung cancer who have been treated previously with chemotherapy (platinum doublet) and crizotinib Multiple phase 3 Closed Anaplasic lymphoma kinase (ALK) positive